Silexion Therapeutics Corp. revealed that its executive team, including CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar, will participate in the 2026 BIO International Convention in San Diego, CA from June 22 to 25. The event aims to showcase the company's groundbreaking RNA interference therapies for KRAS-driven cancers. The clinical-stage biotechnology company specializes in this area and is focused on developing innovative treatments.